



## Angiogenesis – dependent Diseases

Dear TiP-TV Subscriber:

Thank you for registering for Current Concepts in Pediatric Health Care Series. This educational series is available to you at no additional charge with your TiP-TV subscription.

This program will air on the following dates and times.

**Tuesday, June 13, 2006, 1:00 – 2:00**  
**Thursday, June 15, 2006, 11:00 – 12:00**  
**Tuesday, June 20, 2006, 11:00 – 12:00**  
**Thursday, June 22, 2006, 2:00 – 3:00**

**All times are Eastern time.**

Participants can register by visiting [www.chbpediatriccme.com](http://www.chbpediatriccme.com).

This educational offering is intended for the following healthcare professionals:

Primary Care Physicians, Pediatricians, Pediatric Specialists, Pediatric Subspecialists, Pediatric Nurses, Pediatric Pharmacists



## EDUCATION COORDINATOR CHECKLIST

### Prior to the Meeting:

- ❑ See “Technical FAQs” in the Quick Help section of the TiP-TV Neighborhood for satellite information.
- ❑ Reserve the conference/viewing room.
- ❑ Write the site number and site name on all CME/CE Forms **before** duplicating and distributing to participants. Call TiP-TV at (877) 438-4788 if you do not know your site number.
- ❑ **Either download or print and copy the CME/CE Packet, including the CME/CE Information and CME/CE Evaluation and Post-Test for each participant. Have extras available for those participants who do not register with you before the conference.** Consider having pens/pencils available for participants.
- ❑ You may also choose to make several copies of the Participant Sign-in Sheet available in the room to expedite the registration process.

### Day of the Meeting:

- ❑ Arrive at the auditorium or viewing room at least 30 minutes before the broadcast and tune in to the broadcast signal test. If your site is experiencing technical difficulties, please call **TiP-TV Satellite Solutions (Technical Help Desk): (800) 736-4367**.
- ❑ Set up your registration table; register participants using the Participant Sign-in Sheets.

### After the Broadcast:

#### For participants to obtain CME/CE credit

The following materials will allow participants to apply for CME/CE:

- ❑ **Participant Sign-in Sheet:** Be sure to note at the top the **total number of attendees including viewers who have not requested CME/CE credits.**
- ❑ **Please also fill in Site Coordinator contact information in case MESG needs to reach you.**
- ❑ **CME/CE Information:** Please download or print and photocopy for all participants (includes objectives, accreditation information, disclosures, etc.).



- ❑ **Participant CME/CE Evaluation and Post-Test:** Please download or print and photocopy for all participants and collect them from participants who wish to turn them in.
- ❑ Collect all Sign-in Sheets, Evaluations, and Post-Tests that are returned to you. Please remind participants that incomplete or illegible forms will not be processed for credit.

Mail these forms to:

**Medical Education Solutions Group (MESG)  
5523 Research Park Drive, Suite 220  
Baltimore, MD 21228  
Or FAX to 443-543-5210**

**NOTE: Incomplete or illegible forms will not be processed for credit.  
Participant's degree must be indicated on forms for proper credit  
certification.**

Directions for submitting CME/CE paperwork are also included on the individual forms should participants choose to mail them individually. Allow four to six weeks from receipt of forms for delivery of certificates. All responses are for continuing education processing only.

CME/CE credit can also be obtained online at [www.chbpediatriccme.com](http://www.chbpediatriccme.com).

Should you have any questions related to this conference airing on TiP-TV or as an online course, please call TiP-TV Customer Service, toll-free, at (877) 438-4788.

For CME/CE questions, contact Medical Education Solutions Group (MESG) at (443) 543-5205.

For questions about nursing/pharmacy accreditation, contact Medical Education Collaborative at (303) 420-3252.

We want your experience with this series to be a complete success at your site. Thank you.





## CME/CE Information

### Program Title

Angiogenesis – dependent Diseases

### Program Learning Objectives

At the conclusion of this activity, participants should be able to:

- Describe the role of angiogenesis in supporting tumor growth
- Discuss therapeutic agents that have anti-angiogenic properties
- Describe how agents with anti-angiogenic properties can be used to treat vascular anomalies and tumors

### Program Faculty

Judah Folkman, MD

Senior Associate in Surgery, Children's Hospital Boston

Director of the Vascular Biology Laboratory, Children's Hospital Boston

Julia Dyckman Andrus Professor, Harvard Medical School

### Target Audience

Primary Care Physicians, Pediatricians, Pediatric Specialists, Pediatric Subspecialists, Pediatric Nurses, Pediatric Pharmacists

### Series Purpose and Statement of Need

***Current Concepts in Pediatric Health Care*** is unique and the first-of-its-kind pediatric lecture series that will allow world-renowned pediatric specialists to reach healthcare providers at medical institutions nationally and internationally.

The programs are case-based and delivered in a patient-case study format. Each one-hour program will explore the diagnosis and treatment of pediatric diseases or conditions, using the latest clinical research data available.

These topics were chosen with input from previous surveys of primary care providers attending previous continuing education programs offered by Children's Hospital, Boston. They also were chosen by the expert opinion of the Committee on Continuing Education and the opinions of Hospital officials familiar with current practices in pediatric care internationally.

Families want the best care available when their child has a health problem. That high level of care evolves from a successful partnership between the child's pediatrician and specialty experts. The pediatrician must be familiar with the latest approaches to diagnosis and management of complex children's diseases and conditions in order to know what tests to order in their assessment, when to refer the child to the specialist, and how medical management should proceed. The pediatrician needs information on

04/06

5

Sponsored By

Airing on:

TiP-TV™

MESG  
MEDICAL EDUCATION SOLUTIONS GROUP



how to utilize the advice of the specialist in his office care to maximize the benefit to the child and his or her family.

It is challenging for community-based pediatricians, pediatric subspecialists, as well as other healthcare providers involved in the care of children, to stay abreast of innovations in advanced pediatric care, as these innovations typically emerge in large tertiary care centers distant from community based care. Understanding innovations in advanced pediatric care is critical to optimal tertiary care utilization, and referral decisions, by community-based pediatricians and pediatric subspecialists. Understanding the innovations in advanced pediatric care is critical to optimal continuing care delivered by community based pediatricians and pediatric subspecialists.

**Program Purpose**

Solid tumors depend on angiogenesis to survive, and investigators have been examining the place of antiangiogenic agents in the antitumor armamentarium since 1971. Beginning in the mid 1990's, there has been an increase in the use of these agents to combat malignancy. Currently antiangiogenic agents have been successfully used in a number of malignancies to induce complete and durable remission, with minimal side effects. Considering recent data on the long-term second cancer rate in children given conventional chemotherapy, pediatricians should be familiar with this effective and safe alternative to conventional agents.

**Sponsorship Statement**

This continuing medical education activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and is sponsored by Medical Education Solutions Group (MESG).

**Accreditation Statement**

MESG is accredited by the ACCME to provide continuing medical education for physicians.

Nursing and pharmacy credits made possible through the cosponsorship of Medical Education Collaborative and MESG. For questions about the accreditation of this program, please contact Medical Education Collaborative at (303) 420-3252 or e-mail [inquire@meccme.org](mailto:inquire@meccme.org).



**Credit Designation**

**Physicians**

MESG designates this educational activity for a maximum of 1.0 category 1 credit per session toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.



**Nurses**

Approved for 1.2 contact hours of continuing education for RNs, LPNs, LVNs and NPs. This program is cosponsored with Medical Education Collaborative, Inc. (MEC) and Medical Education Solutions Group. MEC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider Number CEP 12990, for 1.2 contact hours.

**Nurse Practitioners**

MESG is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA category 1 credit.

**Physician Assistants**

The American Academy of Physician Assistants (AAPA) accepts AMA category 1 CME credit for the PRA from organizations accredited by ACCME. MESG is accredited by ACCME to provide continuing medical education for physicians, and will provide physician assistants who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA category 1 credit.



**Pharmacists**

1.0 contact hours (0.10 CEUs) of credit for pharmacists. Approval of this course for pharmacists is under a cosponsorship agreement between Medical Education Collaborative, Inc. (MEC) and Medical Education Solutions Group. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE #815-999-06-044-H01. The program is designed for all pharmacists.

**Disclosure Policy**

As a provider accredited by the ACCME, faculty members, authors, planners, and managers who affect the content of a CME activity are required to disclose to MESG financial relationships they have with commercial interests associated with this CME activity of any amount over the past 12 months only.

**Faculty Disclosure**

Judah Folkman, MD has no financial relationship to disclose.

**MESG Disclosure**

The employees of Medical Education Solutions Group have no financial relationship to disclose.



### **MEC Disclosure**

Employees of Medical Education Collaborative, the accredited provider of nursing and pharmacy credits for this activity, have disclosed that they have no significant financial relationships.

### **Acknowledgement of Commercial Support**

This educational series is supported through an educational grant from Amgen, Cephalon, and Nutricia.

### **Educational Design**

This program is available in two formats: satellite video broadcast and online archived version. Participants may earn credit for participating in one of the formats.

### **Medium**

Live, videotaped with PowerPoint presentation offered via satellite broadcast, and archived for rebroadcast.

### **Hardware/Software Requirements**

#### ***Operating System***

Microsoft® Windows® 98, NT, 2000, XP, 2003

#### ***Browser/PDF Viewer***

Microsoft Internet Explorer 6.0

Adobe Acrobat Reader® 6.0

#### ***Media Player***

Windows Media® Player 7.1 or higher, OR

RealPlayer® Basic 8 or higher

#### ***Connection Type***

High bandwidth (300k) is strongly recommended

Low bandwidth (100k) results in less than optimal quality

Dial-up/modem is not recommended

### **Unlabeled/Unapproved Uses Notice**

Faculty (speakers) have agreed to disclose to the participants when products or procedures being discussed are off-label, experimental, and/or investigational (not FDA approved) or any limitations that are presented, such as data that are still investigational.

### **Disclaimer**

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

04/06

8

Airing on:

TiP-TV™

Sponsored By

**MESG**  
MEDICAL EDUCATION SOLUTIONS GROUP



**Statement of Evidence-Based Content**

Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME accredited provider of CME, it is the policy of MESHG to review and assure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the

practice of medicine. MESHG is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

MESHG is not liable for any decision made or action taken in reliance upon the information provided through this activity.



## How to Receive CME/CE Credit

In order to receive CME/CE credit, participants must view the CME/CE materials, view the presentation, complete the post-test and evaluation, and return the forms to:

**Medical Education Solutions Group (MESG)**  
**5523 Research Park Drive, Suite 220**  
**Baltimore, MD 21228**  
Or **FAX to 443-543-5210**

Allow four to six weeks from receipt of forms for delivery of certificates. Please note that participants can only receive credit for viewing a session once.

CME/CE credit can also be obtained online at [www.chbpediatriccme.com](http://www.chbpediatriccme.com).

**NOTE: Incomplete or illegible forms will not be processed for credit. Participant's degree must be indicated on forms for proper credit certification.**

### Dates of Release:

**Tuesday, June 13, 2006, 1:00 – 2:00**  
**Thursday, June 15, 2006, 11:00 – 12:00**  
**Tuesday, June 20, 2006, 11:00 – 12:00**  
**Thursday, June 22, 2006, 2:00 – 3:00**

**All times are Eastern time.**

**Expiration Date:** June 12, 2007

**Time Required to Complete This Activity:** One Hour

### ADA Statement

MESG fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Jennifer Tornabene, CME Coordinator, MESG, at (443) 543 5207 to receive assistance.

© 2006, Medical Education Solutions Group



### Angiogenesis – dependent Diseases CME/CE Post-Test

Release: June 13, 2006      Expiration: June 12, 2007

To earn CME/CE credit, complete the evaluation and post-test, answering 70 percent of the post-test questions correctly. Select the best answer and circle next to each question below. Please use all capital letters and print your name, address, and other information requested below. Keep a copy of the completed post-test and evaluation for your files.

Send originals to:

Medical Education Solutions Group (MESG), 5523 Research Park Drive, Suite 220, Baltimore, Maryland, 21228, or fax to (443) 543-5210 by June 12, 2007. Allow four to six weeks from receipt of post-test for delivery of certificate.

**Contact information, degree, attestation, and signature required for certificate:**

First/Last Name \_\_\_\_\_

Address 1 \_\_\_\_\_

Address 2 \_\_\_\_\_

City/State/Zip \_\_\_\_\_

Phone \_\_\_\_\_ E-mail \_\_\_\_\_

**Degree:** (please check)

MD provide specialty \_\_\_\_\_  DO

Pharm       PharmD

RN       PhD       MBA       PA

NP       LPN       Other \_\_\_\_\_

Nurses provide license # \_\_\_\_\_

**Attestation of Credit:**

Physicians

I claim  .5  1.0 credits of AMA PRA category 1 CME credit

Pharmacists

I claim  1.0 CEUs of credit for pharmacists

Nurses

I claim  1.2 contact hours of nursing credit

**How did you view the program?**

Satellite TV       Web

Signature \_\_\_\_\_ Date \_\_\_\_\_



Angiogenesis – dependent Diseases

CME/CE Post-test

Name \_\_\_\_\_

- 1) True or False: One explanation for why individuals with Down syndrome are the most protected of all humans against cancer, is that they have a higher level of circulating endostatin.
  - a) True
  - b) False
  
- 2) Children and adolescents with recurrent high grade giant cell tumors of the maxilla and jaw may now in many cases avoid radiotherapy and be treated with nerve- and teeth-preserving surgery followed by which angiogenesis inhibitor, for 8-12 months?
  - a) Doxycycline
  - b) Zolendronate (Zometa)
  - c) Interferon-alpha
  - d) Avastin
  
- 3) The target of two angiogenesis inhibitors now being used to treat age-related macular degeneration in adults, is:
  - a) bFGF (basic fibroblast growth factor)
  - b) HGF (hepatocyte growth factor)
  - c) VEGF (vascular endothelial growth factor).
  - d) PDGF (platelet derived growth factor)
  
- 4) True or False. Cancer, rheumatoid arthritis, and hemangiomas, are all examples of angiogenesis-dependent diseases.
  - a) True
  - b) False
  
- 5) One mechanism by which interferon alpha suppresses the growth of life-threatening hemangiomas is that it blocks the synthesis of which of the following?
  - a) VEGF
  - b) bFGF
  - c) Angiogenin
  - d) PDGF



Angiogenesis – dependent Diseases

CME/CE Post-test

Name \_\_\_\_\_

- 6) Why can severe hypothyroidism appear in an infant with a very large burden of hemangioma (i.e., in the liver)?
- a) There is high blood flow through the hemangioma.
  - b) The hemangioma eventually undergoes involution.
  - c) A deiodinase is produced by the hemangioma.
  - d) A hemangioma is a “metastasis” from the placenta.
- 7) All of the following statements regarding anti-angiogenic chemotherapy (“metronomic” therapy) are true EXCEPT:
- a) Induces less acquired drug resistance.
  - b) Is administered at maximum tolerated doses.
  - c) Shifts the target of chemotherapy from tumor cells to vascular endothelial cells.
  - d) Does not usually require prolonged off-therapy intervals for restoration of gut epithelium and bone marrow cells.
- 8) Endogenous angiogenesis inhibitors include which of the following?
- a) Endostatin
  - b) 2-methoxyestradiol
  - c) Tetrahydrocortisol
  - d) A, B, and C
- 9) Which of the following statements regarding the use of an anti-angiogenesis agent in patients with macular degeneration is true?
- a) 95% of patients in a clinical trial who were randomized to ranibizumab retained their vision for one year
  - b) 40% of patients in a clinical trial who were randomized to ranibizumab had improved vision
  - c) Patients randomized to placebo experienced a loss of visual acuity
  - d) A, B, and C
- 10) Which of the following parameters responds better in animals to low dose alpha interferon than high dose alpha interferon?
- a) Tumor weight
  - b) Serum bFGF
  - c) Mean number of vessels/100 X field on microscopy
  - d) A, B, and C



Angiogenesis – dependent Diseases

CME/CE Evaluation

Name \_\_\_\_\_

### Angiogenesis – dependent Diseases CME/CE Evaluation

Release: June 13, 2006      Expiration: June 12, 2007

**1. On a scale of 1 to 5, with 5 = “completely” and 1 = “not at all,” please rate the extent to which you achieved the learning objectives:**

a. Describe the role of angiogenesis in supporting tumor growth

<u>5</u>	<u>4</u>	<u>3</u>	<u>2</u>	<u>1</u>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

b. Discuss therapeutic agents that have anti-angiogenic properties

<u>5</u>	<u>4</u>	<u>3</u>	<u>2</u>	<u>1</u>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

c. Describe how agents with anti-angiogenic properties can be used to treat vascular anomalies and tumors

<u>5</u>	<u>4</u>	<u>3</u>	<u>2</u>	<u>1</u>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**2. Please indicate the degree to which you agree or disagree with the following:**

a. Activity was effective in meeting identified needs

Strongly <u>Agree</u>	<u>Agree</u>	<u>Disagree</u>	Strongly <u>Disagree</u>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

b. Format of activity enhanced achievement of learning objectives

Strongly <u>Agree</u>	<u>Agree</u>	<u>Disagree</u>	Strongly <u>Disagree</u>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>



Angiogenesis – dependent Diseases

CME/CE Evaluation

Name \_\_\_\_\_

c. Activity was balanced and free of commercial bias

Strongly				Strongly
<u>Agree</u>	<u>Agree</u>	<u>Disagree</u>	<u>Disagree</u>	
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

d. Activity will assist me in improving my professional effectiveness

Strongly				Strongly
<u>Agree</u>	<u>Agree</u>	<u>Disagree</u>	<u>Disagree</u>	
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

3. How do you rank this educational activity overall on a scale of 1 to 5, with 5 being the highest?

5       4       3       2       1

4. As a result of participating in this educational activity, will you be making changes to your practice in a manner that improves patient care?

Yes       No

Please explain: \_\_\_\_\_

5. Please rate Judah Folkman, MD on a scale of 1 to 5, with 5 being the highest:

Presentation Skills     5       4       3       2       1

Content                     5       4       3       2       1

Balanced, Objective, Scientifically Rigorous     5       4       3       2       1

Do you feel this presentation was commercially biased in any manner?

yes       no

If yes, please describe: \_\_\_\_\_

6. May we use your e-mail address to notify you of future continuing medical education activities?

yes       no      e-mail: \_\_\_\_\_



Angiogenesis – dependent Diseases

CME/CE Evaluation

Name \_\_\_\_\_

**7. What other clinical topics would you like to see discussed in future CME/CE activities?**

---

---

**8. As part of our ongoing continuous quality improvement effort, we conduct three-month post-activity follow-up surveys to assess the impact of our CME/CE activities on your professional practice. Are you willing to participate in such a survey?**

Yes       No

**9. Would you be willing to participate in a phone call or in-person discussion exploring ways to improve our CME/CE activities?**

Yes       No

**10. Additional comments/questions:**